Whether this is due to specific regulation of the immune system by hormone signalling (or endocrine treatment, as all HR-positive BCs also received hormonotherapy in the PAMELA trial), or if reduced activation of immunity in these tumours is linked to reduced cell death after HER2-targeted treatment and reduced antigen exposure, remains unclear and might hopefully be the subject for further investigation. This evidence concerns the gene ERBB2 and neoplasm.